

Table of Contents

Preface	xix
About the Editors.....	xxiii

SECTION I

Regulatory Considerations for Manufacturing Cellular Therapies in the United States..... 1

Section Editor: Victoria A. Lake, BSc, BA, RAC

1. A Brief History of US FDA Regulation of Human Cells and Tissues	2
<i>Liana Harvath, PhD</i>	
Background	2
HPC from Placental/Umbilical Cord Blood and Peripheral Blood	9
Proposed Approach to Regulation of Cellular and Tissue-Based Products.....	9
Future Directions	14
References/Resources	16
2. The FDA Perspective on the Manufacturing, Production, and Processing of Regulated Cellular Therapies	18
<i>Eric Dollins, PhD; Patrick Lynch, PhD; Prajakta Varadkar, PhD; and Keith Wonnacott, PhD</i>	
General Tips.....	19
cGMPs for Phase 1 Clinical Trials.....	20
Conclusion.....	29
References/Resources	29
3. Regulatory Considerations for Other Cellular Therapies.....	33
<i>Martha Wells, RAC, MPH</i>	
Regulatory Pathways.....	34
Sources of Novel Cellular Therapies	34
Future Considerations	36
References/Resources	36
4. Cellular Therapies Regulated as Combination Products.....	37
<i>Joyce L. Frey-Vasconcells, PhD</i>	
What Is the Definition of a Combination Product?.....	37
Who Determines Which Center Will Have Review Responsibility for a Combination Product?.....	38
Can the Applicant Determine Which Center Will Review the Product?.....	38
What Regulations Need Clarification from the FDA?.....	40
Conclusion.....	43
References/Resources	43

5. The Investigational New Drug Application	44
<i>David H. McKenna, Jr, MD; Victoria A. Lake, BSc, BA, RAC; and Darin J. Weber, PhD</i>	
Overview	45
Chemistry, Manufacturing, and Controls Section	46
References/Resources.	46
Appendix 5-1. Sample Outline for Preparing the Chemistry, Manufacturing, and Controls Section of an Investigational New Drug Application	50
6. Biologics License Applications for Cellular Therapies	52
<i>Rafael Cassata, MS, RAC (US, EU)</i>	
Pre-BLA Submission Activities	52
Fees	54
Review Timelines	54
References/Resources.	56
Appendix 6-1. Sample Outline for the Content and Organization of a Biologics License Application	58
7. Electronic Submissions of Cellular Therapy Investigational New Drug and Biologics License Applications	63
<i>Daniel P. Offringa</i>	
Brief History	63
Advantages of Electronic Submissions over Paper	64
Initial Considerations	64
Finalizing the Submission	65
References/Resources.	66
8. International Regulation of Cellular Therapy Products	67
<i>Rafael Cassata, MS, RAC (US, EU)</i>	
Australia	67
Brazil	68
Canada	69
European Union	70
India	73
Japan	73
Singapore	74
Conclusion	75
References/Resources.	75
Appendix 8-1. Global Cellular Therapy Regulatory Bodies and Organizations	77

SECTION II

Quality Assurance for Cellular Therapy Facilities	81
<i>Section Editors: Lizabeth Cardwell, MT(ASCP), MBA, RAC, and Michele W. Sugrue, MS, MT(ASCP)SBB</i>	
Origins of Quality Concepts	82

Evolution of Cellular Therapy Quality Programs	82
References/Resources	84
9. Quality and Process Control	85
<i>Lizabeth Cardwell, MT(ASCP), MBA, RAC; and Michele W. Sugrue, MS, MT(ASCP)SBB</i>	
Quality Control	85
Change Control	88
Process Verification and Validation	90
Process Simulation	91
Product Contamination and Cross-Contamination	92
Donor Eligibility	93
Recovery or Collection	94
Tracking and Traceability	95
Storage Controls	96
Transportation Controls	96
Receipt, Predistribution Shipment, and Distribution of HCT/Ps	97
References/Resources	98
Appendix 9-1. Incoming Critical Supplies	100
Appendix 9-2. Sample Change-Control Form	101
Appendix 9-3. Document Format for General Process Validation Protocol	102
Appendix 9-4. Product Changeover Record	103
Appendix 9-5. Sample Product Tracking Form	104
10. Cell and Tissue Donor Qualification Processes: Evaluation and Eligibility	105
<i>Lisa Phillips Johnson, MT(ASCP)SBB, CQA(ASQ)COM-OE, and Rafael Cassata, MS, RAC (US, EU)</i>	
Overview	105
Quality Management Program Topics	106
Medical Suitability	107
Other Donor Testing Topics	112
Donor Eligibility Determination	113
Other Donor Eligibility Topics	115
Conclusion	116
References/ Resources	116
11. Human Resources in the Cellular Therapy Facility	118
<i>Kevin L. Bundy, BB, MT(ASCP)SBB; Brenda Alder, MS, MT(ASCP)SBB; Lizabeth Cardwell, MT(ASCP), MBA, RAC; and Michele W. Sugrue, MS, MT(ASCP)SBB</i>	
Personnel Requirements and Selection	118
Applicant Interview	119
Academic Transcripts	119
Orientation	120
Training/Retraining	120
Competency	120
Performance Appraisals	121
Continuing Education	121
Position Description Review Process	122

Proficiency Testing	122
References/Resources	123
Appendix 11-1. Sample Policy for Personnel, Training, and Competency	124
Appendix 11-2. Sample Position Description for Cellular Therapy Specialist	126
Appendix 11-3. Sample Position Description for Quality Assurance Specialist	128
Appendix 11-4. Sample Cellular Therapy Facility Training Checklist	130
Appendix 11-5. Sample Competency Assessment Policy	132
Appendix 11-6. Sample Cellular Therapy Facility Competency Assessment Checklist	134
Appendix 11-7. Sample Competency Assessment Form	135
Appendix 11-8. Sample Policy for a Continuing Education Program	138
12. Equipment Management in the Cellular Therapy Facility	139
<i>Tao Wang, MS, and Dave Krugh, MT(ASCP)SBB, CLS, CLCP(NCA)</i>	
Equipment Qualification	139
Equipment Quality Control	141
Record Retention	142
References/Resources	142
Appendix 12-1. Critical Equipment Selection Form	143
Appendix 12-2. Equipment Qualification Form	145
Appendix 12-3. New Equipment Qualification Checklist	150
Appendix 12-4. Equipment Activity Log	151
Appendix 12-5. Equipment Requalification Checklist	152
Appendix 12-6. Equipment Cleaning Log	153
13. Quality Assurance of Supplies and Materials for Cellular Therapy Facilities	154
<i>Renee Smilee, MT(ASCP)</i>	
Defining Critical Materials	154
Supplier Agreements	155
Audits	156
Receipt, Inspection, and Testing of Supplies	156
Appendix 13-1. Supplier Qualification Survey	158
Appendix 13-2. Supplies Approved Inventory Log	159
Appendix 13-3. Material/Component Inspection Form	160
14. Audits of Cellular Therapy Facilities	161
<i>Sharon E. Tindle, MS, CQA(ASQ)</i>	
External Audits	161
Internal Audits	162
Audit Schedule	162
Auditor Qualification and Training	163
Auditing Methods	164
References/Resources	164

15. Documents and Records	166
<i>Leigh Sims Poston, BS, MT(ASCP), and Betsy W. Jett, MT(ASCP), CQA, CQM/OE(ASQ)</i>	
Documentation as Part of a Value-Driven Process	166
Characteristics of an Effective Document	167
Document Management	169
Characteristics of an Effective Record	170
Record Management	170
Summary	172
References/Resources	172
Appendix 15-1. Document Example: HPC(A) Collection Label	174
Appendix 15-2. Document Example: HPC(M) Collection Label	174
Appendix 15-3. Record Example: HPC(A) Collection Label	175
Appendix 15-4. Record Example: MNC(A) Collection Label	175
Appendix 15-5. Record Example: T Cells(A) Final Label	176
16. Standards and Accreditation for Cellular Therapies	177
<i>Carolyn A. Keever-Taylor, PhD</i>	
Cellular Therapy Product Standards	178
AABB	178
Foundation for the Accreditation of Cellular Therapy	181
National Marrow Donor Program	183
The College of American Pathologists	184
ISBT 128 for Cellular Therapy	185
Circular of Information	185
Standards Harmonization	186
Achieving Accreditation	186
References/Resources	187
17. Approaches to Validation for Cellular Therapy Products	188
<i>Timothy Houck and Gary C. du Moulin, PhD, MPH</i>	
Unique Requirements for the Validation of Cellular Therapy Products	189
Validation of Ancillary Processes	190
Elements of a Validation Program	190
PPQ for CT Products	194
Maintaining a State of Validation	196
Process or Product Changes	196
Conclusion	197
References/Resources	197

SECTION III**Facilities: General Procedures 199***Section Editor: John R. Godshalk, MSE, MBA***18. Key Considerations and General Procedures for Facilities 201***John R. Godshalk, MSE, MBA, and Robert A. Preti, PhD*

Manufacturing Area Requirements	202
Manufacturing Support Area Requirements	204
QC Laboratory and Microbiology Laboratory Requirements	204
Information Technology Infrastructure	205
Mechanical and Utility Requirements	205
Warehouse Requirements	206
References/Resources	206

19. Aseptic Processing 207*John Godshalk, MSE, MBA*

The Environment	207
Personnel	208
Closed Systems	209
Validation of Aseptic Processing	209
Reference/Resource	210

20. Cross-Contamination Issues in the Manufacture of Cellular Therapy Products 211*John Finkbohner, PhD*

Identifying Process Risks: Process Mapping	212
Minimizing Process Risks: Optimizing Manufacturing Unit Operations and Validating Unit Operation Robustness	212
Minimizing Process Risks: Controlling Routine Operation Variables	214
Conclusion	216
References/Resources	216

21. Computer Systems in the Cellular Therapy Facility 217*A.A. Geoffrey Browne and John R. Godshalk, MSE, MBA*

Computer System Selection	217
Computer System Validation	219
Computer System Operation	223
Regulations for Software Used in the Production of Cellular Therapy Products	224
Summary	225
References/Resources	225
Appendix 21-1. Sample Computer System Selection Plan	226
Appendix 21-2. Sample Computer System Installation Plan	227
Appendix 21-3. Sample Computer System Validation Plan	228
Appendix 21-4. Sample Computer System Test Case	229

22. Maintaining Safety in Cellular Therapy Facilities through Quality Assurance 231

Florinna Estioco Dekovic, MT(ASCP)BB, CQA(ASQ)

The Facility Designed for Security	231
Personal Hygiene Practices.	232
Protection of Personnel in the Cellular Manufacturing Facility	233
Aseptic Technique.	233
Emergency Preparedness and Action Plans	234
Contamination Control	234
Ergonomic Safety	236
Safety in the Use of Compressed-Gas Cylinders	236
Material Safety Data Sheets and Hazardous Materials	237
References/Resources	237

SECTION IV

Process and Product Development for Cellular Therapeutics in Early-Phase Trials 239

Section Editor: Robert Lindblad, MD

23. Building a Team for Cellular Therapies in Early-Phase Trials 241

Deborah A. Wood, MT(ASCP)

Building a Team	241
References/Resources	248

24. Manufacturing for Cellular Therapeutics in Early-Phase Trials 249

Adrian P. Gee, PhD

Manufacturing Regulations	249
Development of the Manufacturing Process	250
Manufacturing Methods.	252
Chemistry, Manufacturing, and Controls Section of the IND Application.	255
Product Distribution, Administration, Recalls, and Complaints	257
Conclusions	257
References/Resources	258
Appendix 24-1. FDA Guidance Documents for the Cellular Product Manufacturer.	259

25. Preclinical Testing for Early-Phase Cellular Therapy Products 262

John M. Centanni, MS

Preclinical Study Conduct	263
Proof of Concept Studies	265
Preclinical Safety Testing	268
Preclinical Safety Protocol Design.	270
Conclusions	271
References/Resources	272
Appendix 25-1. Sample Pulmonary/Mesenchymal Stem Cell Preclinical Animal Safety Study Report: Table of Contents.	273

26. Key Considerations in Developing Pluripotent Stem-Cell-Derived Therapeutics	277
<i>Derek J. Hei, PhD</i>	
Early-Stage Development Considerations	278
Production of Material for Preclinical Animal Studies	280
PSC Bank Production and Testing	280
Production of the Final Cell Product	284
References/Resources	287

SECTION V

Collection of Cells for Transplantation and Other Cellular Therapies 291

Section Editor: Michele Cottler-Fox, MD

Background and Historical Perspective	292
Current State of the Field	292
Overview of Section V	292
Future Directions	293
Reference/Resource	293
27. Bone Marrow Collection	294
<i>Thomas R. Spitzer, MD</i>	
Development of Human Marrow Collection Technique	295
Anesthesia	296
Collection Technique	297
Postoperative Care	298
Nucleated Cell Yield and Quality Control	298
Donor Complications	300
Additional Issues	302
Bone Marrow Harvesting and Regenerative Medicine	303
Conclusions	303
References/Resources	303
28. Collection of Cellular Therapy Products by Apheresis	306
<i>Laura S. Connelly-Smith, MBBCh, DM, and Michael L. Linenberger, MD, FACP</i>	
HPC Mobilization Regimens and Kinetics	308
Instruments and Methodologies for HPC(A) Collection	310
Standard Procedures for HPC(A) Collections	312
Collecting HPC(A) from Pediatric Donors	314
Adverse Effects and Complications of CD34+ Cell Mobilization and HPC(A) Collection	314
References/Resources	317
Appendix 28-1. Examples of Treatment Plans from Three Institutions for Adult Mononuclear Cell Collection by Leukocytapheresis	326
Appendix 28-2. Examples of Treatment Plans from Three Institutions for Adult Large-Volume Mononuclear Cell Collection by Leukocytapheresis	329
Appendix 28-3. Example of a Treatment Plan for Modified Anticoagulation for Apheresis	331
Appendix 28-4. Example of an Apheresis Flow Sheet	333

Appendix 28-5. Cellular Therapy—Hematopoietic Progenitor Cell (HPC) Apheresis Disclosure Form	335
29. Umbilical Cord Blood Collection	337
<i>Joanne Kurtzberg, MD</i>	
Collection Methods Refined	338
Comparing Cord Blood Collection Methods	339
Microbial Contamination: In Utero vs Ex Utero	341
Other Factors That Affect UCB Collection Quality	341
Techniques to Improve Cord Blood Collection	342
Summary	343
References/Resources	344
30. Collection of Other Cells and Tissues	346
<i>Naynesh R. Kamani, MD</i>	
Cells of Hematopoietic Origin	347
Cells of Nonhematopoietic Origin	351
Other Cells and Tissues Currently Collected for Research and Clinical Trials	355
Regulatory Requirements	356
Summary	357
References/Resources	357
<hr/>	
SECTION VI	
Methods for Cells and Tissues for Therapeutic Use	359
<i>Section Editors: Diane Kadidlo, MT(ASCP)SBB, and David H. McKenna, Jr, MD</i>	
31. Basic Cellular Therapy Manufacturing Procedures	361
<i>David H. McKenna, Jr, MD</i>	
Basic Procedures	361
References/Resources	366
32. Umbilical Cord Blood Processing	368
<i>Philip H. Coelho, BSME; Diane Kadidlo, MT(ASCP)SBB; and John Chapman, PhD</i>	
Manual Processing of Cord Blood	369
Automated Processing of Cord Blood	369
Current State of the Field	373
References/Resources	374
33. Hematopoietic Progenitor Cell Graft Modification: Cell Enrichment or Depletion	376
<i>Diane Kadidlo, MT(ASCP)SBB</i>	
Cell Isolation Methods	377
Cell Enrichment	377
References/Resources	379

34. Cell Separation by Counterflow Centrifugal Elutriation	381
<i>Julie Edwards, BS, MT(ASCP)</i>	
References/Resources.	383
35. Hematopoietic Progenitor Cell Culture and Expansion	384
<i>John D. McMannis, PhD</i>	
HPC Expansion Overview.	384
UCB Expansion	385
Methods	386
Culture Vessels and Devices	386
References/Resources.	387
36. Regulatory T Cells	388
<i>Keli L. Hippen, PhD, and David H. McKenna, Jr, MD</i>	
References/Resources.	389
37. Natural Killer Cells.	391
<i>David H. McKenna, Jr, MD, and Jeffrey S. Miller, MD</i>	
References/Resources.	392
38. T-Cell Expansion: Cytotoxic T Cells	393
<i>Jerome Ritz, MD</i>	
Applications	394
Methods for In Vitro Isolation and Expansion.	395
Conclusion	397
References/Resources.	397
39. Allogeneic T-Cell Therapy Using Rapamycin-Resistant CD4+ T Cells (T-Rapa Cells).	400
<i>Daniel H. Fowler, MD; Vicki Fellowes, MT(ASCP); and Hanh Khuu, MD</i>	
Current State of the Field	402
Future Directions.	403
References/Resources.	403
40. Human Mesenchymal Stromal Cells	405
<i>Karen Bieback, PhD, and Hermann Eichler, MD</i>	
Production of Human MSCs	406
Characterization of MSCs In Vitro	410
Conclusion	413
References/Resources	414

41. Dendritic Cell Vaccines	418
<i>Lisa H. Butterfield, PhD</i>	
References/Resources	419
42. Pancreatic Islet Cells	420
<i>Elina Linetsky, PhD, and Camillo Ricordi, MD</i>	
Historical Perspective	421
Donor Selection	423
Islet Isolation	423
Islet Purification	426
References/Resources	427
43. Human iPS Cells—cGMP Production	430
<i>Patrick Walsh, MSc; Kristin Voltzke, MPH; Ann M. Parr, MD, PhD; and James R. Dutton, PhD</i>	
References/Resources	432
44. Regenerative Medicine Approaches for Cell and Tissue Therapies	433
<i>Prafulla Chandra; Bryan Tillman, MD, PhD; Anthony Atala, MD; and James J. Yoo, MD, PhD</i>	
Components of Regenerative Medicine	434
Regenerative Medicine Therapies	435
Tissue-Based Regenerative Therapies	437
Summary	440
References/Resources	440
45. Cryopreservation of Cellular Therapy Products	444
<i>Allison Hubel, PhD, and Aby J. Mathew, PhD</i>	
Elements of a Cryopreservation Protocol	445
Summary	451
References/Resources	451
46. Cryopreservation Containers for Cellular Therapy Products	453
<i>Herbert M. Cullis, MT</i>	
Regulations	453
Materials	454
Cryoprotectants	454
Cassettes	454
Overwraps	455
Laboratory Practices	455
Controlled-Rate Freezing	455
References/Resources	456

SECTION VII**Handling of Processed Cellular Therapy Products. 457***Section Editor: Fran Rabe***47. Thawing and Infusing Cellular Therapy Products 459***Richard L. Haspel, MD, PhD*

Thawing of Cellular Therapy Products 459

Infusion of Cellular Therapy Products 461

References/Resources. 465

48. Cellular Therapy Product Release 468*Fran Rabe*

Quality Unit Role. 468

Typical Product Release Criteria 469

Quality Unit Review of Manufacturing for Release 470

Two-Phased Review. 471

Handling Lot-Release Criteria That Have Not Been Met 471

Quality Unit Rejection of Product 472

Management of Post-Lot-Release “Unexpected” Information 472

References/Resources. 472

Appendix 48-1. Quality Unit Review for Allogeneic Products with Modular Batch Production

Record (BPR). 474

Appendix 48-2. Quality Unit Review for Autologous Products with Placebo 477

Appendix 48-3. Quality Unit Review for Autologous Tissue Products 479

Appendix 48-4. Quality Unit Review of Autologous Products with Placebo Type 2 481

49. Transportation and Shipping of Cellular Therapy Products. 483*Donna Regan, MT(ASCP)SBB, and Angela Yost, MLS(ASCP)CM*

Products 483

Equipment 484

Limitations and Recommendations. 486

Responsibilities of Personnel Involved with Transport 487

Communication: General Guidelines 488

Logistical Considerations 488

Quality Control: Dry Shippers 489

Quality Control: Noncryopreserved Shipping Containers 490

Conclusion 493

References/Resources. 493

SECTION VIII**Biorepositories 495***Section Editor: Elizabeth L. Wagner, MPH*

References/Resources. 496

50. Issues in Operating a Human Tissue Biorepository Supporting Biomedical Research	497
<i>William E. Grizzle, MD, PhD; Katherine C. Sexton, MBA; and Walter C. Bell, MD</i>	
Goals and Design	497
Collection of Human Tissue Specimens	499
Routine and Special Processing of Human Tissue	500
Biorepository Science and the Effects of Long-Term Storage	501
Distribution of Biorepository Specimens to Investigators	503
The Importance of a Quality Management System	503
Education and Training	504
Annotation of Biorepository Specimens	505
Bias Affecting the Usefulness of Biorepository Specimens	505
Financial Management and Cost Recovery	506
Informatics in Biorepositories	506
Safety in Biorepositories	507
Conclusion	507
References/Resources	508
51. Regulatory Considerations for Research Biorepositories	510
<i>Scott D. Jewell, PhD, and Madeleine A. Williams, MA</i>	
Terms and Definitions	510
Regulatory Considerations for Biorepositories	512
Responsibility for Data Handling by Biorepositories	514
Biorepository Structures	518
References/Resources	519
52. Current Ethical Issues in Biospecimen Research: Communicating Research Information to Participants	521
<i>Michele Russell-Einhorn, JD</i>	
Regulatory Background	522
Collecting the Research Specimens	522
Disclosing Results	523
Disclosure Expectations	524
Conclusion	524
References/Resources	525

SECTION IX

Assessment and Characterization of Cellular Therapy Products 527

Section Editor: M. Victor Lemas, PhD

Current State of the Field	528
Section Overview	528
Future Directions	529

53. Integrated Analysis of Hematopoietic Cellular Therapy Product Quality	530
<i>Michael H. Creer, MD, FCAP</i>	
Counting Cells in HCT Products	531
HCT Product Viability and Function	535
Indirect Viability Assessment Based on Dye Uptake and Staining	535
Direct Viability Assessment Based on Stem/Progenitor Cell Function	538
Effects of Time and Temperature on HPC(CB) Product Stability	539
Effect of Cryopreservation Freeze-Thaw Cycle on HPC(CB) Product Quality	540
Effects of Cryopreservation and Thawing on HSC Functional Assessment	543
References/Resources	543
54. Cell Counts and Differentials of Cellular Therapy Products	545
<i>Carolyn A. Keever-Taylor, PhD</i>	
HPC(M)	546
HPC(M) and HPC(CB) Nucleated Cell Counts	546
HPC(M) Differentials	548
Apheresis HPC Products	550
HPC(A) WBC Counts	550
Mobilized Peripheral Blood Differentials	550
Sampling and Determination of Product Volume	551
Determination of Cell Numbers and CD34+ Cell Content in Thawed HPC(CB) Products	553
Instruments and Equipment	553
Summary	553
References/Resources	553
55. Assessment of Viability and Apoptosis in Cellular Therapy Products	556
<i>Nicholas J. Greco, PhD, and Lynn O'Donnell, PhD</i>	
References/Resources	557
56. Enumeration of CD34+ Cells by Flow Cytometry	558
<i>D. Robert Sutherland, MSc, and Michael Keeney, FIMLS, FCSMLS(D)</i>	
CD34+ Cell Enumeration Using Multiparameter Cytometry and Sequential Boolean Gating: The International Society of Hematotherapy and Graft Engineering Protocol	559
Critical Issues in CD34+ Cell Enumeration	562
References/Resources	568
57. Colony-Forming Cell Assays for Determining Potency of Cellular Therapy Products	570
<i>Emer Clarke, PhD</i>	
References/Resources	571
58. Bioluminescence Potency Measurement of Cellular Therapy Products	572
<i>Holli Harper, MS, and Ivan N. Rich, PhD</i>	
Criteria for Measurement of HSC Potency	573
References/Resources	574

59. Assessing the Function of Cellular Therapy Products by Measurement of Cytoplasmic Aldehyde Dehydrogenase	576
<i>Tracy Gentry, MT(ASCP), and Kevin Shoulars, PhD</i>	
Background	576
ALDH ^{br} Cells: A Marker of Potency for Cord Blood	578
References/Resources	580
60. Cell Assessment and Characterization: Characterizing T-Cell Populations and Functions	582
<i>Kimberly A. Noonan, PhD, MPH, and Ivan Borrello, MD</i>	
Basic Principles of Flow Cytometry	583
An Introduction to T-Cell Biology	583
Phenotypic Analysis of T cells through Flow Cytometry	584
Functional Analysis of T Cells	585
Important Note: Specimen Procurement and Viability	587
References/Resources	587
61. HLA Typing for Cellular Product Characterization and Identity Testing	589
<i>Terry O. Harville, MD, PhD</i>	
HLA Discovery	590
Serologic, “Low-Resolution” HLA Typing	591
HLA Typing by DNA Analysis	593
HLA Nomenclature	593
HLA Typing by Molecular Techniques	594
High-Resolution HLA Typing by SSP-PCR Technique	596
HLA Typing by Sequence-Based Technology	597
Comparisons of DNA Typing	599
Next-Generation Sequencing Analysis	601
HLA Typing as an Identity Test	602
References/Resources	602
62. The Use of Blood Grouping for Identity Testing of Cellular Therapy Products	604
<i>Ellen Areman, MS, SBB(ASCP)</i>	
Reference/Resource	605
63. Assessing Cellular Therapy Products for Microbial Contamination	606
<i>John Duguid; Hanh Khuu, MD; and Gary C. du Moulin, PhD, MPH</i>	
Special Challenges Pertaining to Sterility Testing of CT Products	608
References/Resources	611
64. Endotoxin Testing of Cellular Therapy Products	612
<i>Diane Kadidlo, MT(ASCP)SBB</i>	
References/Resources	613

65. Detection of <i>Mycoplasma</i> Contamination	614
<i>Peter Bugert, PhD</i>	
Common Characteristics of <i>Mycoplasma</i> Species	615
Methods for <i>Mycoplasma</i> Detection	615
<i>Mycoplasma</i> Detection Based on Real-Time PCR	616
Future Directions of NAT-Based <i>Mycoplasma</i> Detection	618
References/Resources	618
66. Pancreatic Islet Characterization	620
<i>Elina Linetsky, PhD</i>	
References/Resources	622
67. Validation of Test Methods	623
<i>Nina K. Garlie, PhD</i>	
Performance Parameters	624
Conclusion	626
References/Resources	626
Appendix 67-1. Sample Validation Form	627

METHODS SECTION

Method 9-1. Maintaining a Corrective and Preventive Action Program	632
Method 12-1. Selecting and Qualifying Equipment	636
Method 12-2. Equipment Management	642
Method 14-1. Internal Audits for the Cellular Therapy Facility	646
Method 19-1. Aseptic Technique for Cell Processing	647
Method 19-2. Operating and Maintaining the Biological Safety Cabinet	650
Method 27-1. Hematopoietic Progenitor Cell, Marrow [HPC(M)]	
Collection, Processing and Preparation for Shipment	652
Method 28-1. Mononuclear Cell Apheresis Collection Using COBE Spectra	661
Method 28-2. Optia MNC Collection	665
Method 28-3. Stem Cell Collection with Terumo BCT Spectra Optia Using the cMNC	
Program (software version 11.2) with the IDL Collection Set (Art.-Nr. 10310)	676
Method 29-1. Ex Utero Cord Blood Collection Procedure	677
Method 29-2. In Utero Collection of Cord Blood by the Carolinas Cord Blood Bank	690
Method 31-1. Reducing Plasma in Marrow and Hematopoietic Progenitor Cells from	
Apheresis	697
Method 31-2. Separating Bone Marrow Buffy Coat by Using the COBE 2991	699
Method 31-3. HES Sedimentation for Manual Red Cell Removal	701
Method 31-4. Processing Marrow by Using the COBE Spectra for Mononuclear Cell	
Enrichment	702
Method 31-5. Separating Marrow by the Density Gradient Method Using COBE 2991	705
Method 32-1. Processing Cord Blood with the PrepaCyte System	711
Method 32-2. Automated Processing of Umbilical Cord Blood with the Biosafe Sepax	
System and Smart-Max Devices	713

Method 32-3. Automated Volume Reduction of Umbilical Cord Blood Using the AutoXpress System	714
Method 32-4. Automated Processing of Umbilical Cord Blood with the SynGenX-1000 Platform and Related Accessories	716
Method 33-1. Selecting CD34+ Cells by Using the Isolex 300i Magnetic Cell Selection System	718
Method 33-2. Selecting CD34+ Cells by Using the CliniMACS System	721
Method 34-1. Counterflow Centrifugal Elutriation by Using a Floor-Model Centrifuge	725
Method 34-2. Monocyte Enrichment by Using the Elutra Cell Separation System	727
Method 35-1. Ex Vivo Expansion of Selected Hematopoietic Progenitor Cells from Cord Blood	729
Method 36-1. Production of Umbilical Cord-Blood-Derived Regulatory T Cells	734
Method 37-1. Production of Peripheral-Blood-Derived, CD3-Depleted, IL-2-Activated Natural Killer Cells	738
Method 39-1. General Overview of Current T Helper 2 Cell Manufacturing: Rapamycin-Generated, Interleukin-4 Polarized Donor T Cells	742
Method 40-1. Isolating and Characterizing Mesenchymal Stem or Stromal Cells from Marrow	744
Method 40-2. Isolating and Characterizing Mesenchymal Stem or Stromal Cells from Umbilical Cord Blood	747
Method 40-3. Isolating and Characterizing Mesenchymal Stem or Stromal Cells from Adipose Tissue	749
Method 41-1. Culturing and Characterizing Human Dendritic Cell Vaccines.	751
Method 42-1. Isolating Human Islet Cells	757
Method 42-2. Preparing Pancreatic Digestion Media: SERVA Enzyme Preparation.	769
Method 42-3. Preparing Pancreatic Digestion Enzyme: Collagenase and Thermolysin	770
Method 43-1. Current Good Manufacturing Practice Production of Induced Pluripotent Stem Cells from Human Dermal Fibroblasts.	771
Method 45-1. Cryopreserving Cellular Therapy Products in Freezing Bags	777
Method 45-2. Automated Controlled-Rate Freezing, Storage, and Retrieval of Volume-Reduced Cord Blood Units Using the BioArchive System	779
Method 47-1. Thawing of Hematopoietic Progenitor Cells: Laboratory and Bedside	784
Method 47-2. Filtration of Cellular Therapy Apheresis Products	786
Method 47-3. Infusion of Hematopoietic Progenitor Cells in Adult Patients.	787
Method 47-4. Washing Cryopreserved Hematopoietic Progenitor Cells to Remove Dimethyl Sulfoxide	789
Method 47-5. Washing Cellular Therapy Products Using the COBE 2991.	791
Method 47-6. Reconstitutive Thawing: Preparing Frozen Cord Blood Products for Infusion	793
Method 49-1. Shipping Frozen Cord Blood Units.	796
Method 54-1. Partial Plasma Removal from Marrow Samples.	798
Method 54-2. Counting Nucleated Cells in Thawed Cell Therapy Products by Using Single-Platform Flow Cytometry	799
Method 55-1. Determining Cellular Viability by Using Trypan Blue	801
Method 55-2. Determining Viability by Fluorescence Microscopy Using Acridine Orange and Propidium Iodide	803
Method 55-3. Assessing Viability by Measuring Apoptotic Cells by Using Flow Cytometry	805
Method 56-1. Flow Cytometric Enumeration of CD34+ Hematopoietic Progenitor Cells According to ISHAGE Protocol	809
Method 57-1. Hematopoietic Colony-Forming Cell Assays.	824
Method 58-1. Measurement of Umbilical Cord Blood Stem Cell Potency	829

Method 59-1. Analyzing Aldehyde Dehydrogenase-Bright Cells in Umbilical Cord Blood Segments to Assess Cord Blood Quality: Potency Assay Using a Thawed Cord Blood Segment	835
Method 60-1. Simple Schematic for Processing Specimens for Immune Monitoring Studies.	840
Materials, Reagents, and Equipment	840
Method 61-1. Microcytotoxic HLA Class I and Class II Serological Typing (Dynabeads-Isolated Lymphocytes)	842
Method 61-2. LABType Reverse Single-Strand Oligonucleotide (rSSO) HLA TYPING	844
Method 61-3. High-Resolution Sequence-Specific Primer HLA Typing	848
Method 63-1. Cellular Therapy Product Sterility Testing (As Described in USP <71>)	852
Method 63-2. Cellular Therapy Product Sterility Testing Using an Automated Microbial Detection System.	853
Method 64-1. Kinetic-Chromogenic LAL Assay.	855
Method 65-1. <i>Mycoplasma</i> Detection by Real-Time PCR.	858
Method 66-1. Enumerating Pancreatic Islets by Dithizone Staining	860
Method 66-2. Determining Pancreatic Islet Function by Insulin Release	862
Method 67-1. Validating Test Methods.	864
<hr/>	
GLOSSARY	868
INDEX	881